A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes and Hypertension.

Trial Profile

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes and Hypertension.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Pioglitazone; Pioglitazone/azilsartan
  • Indications Hypertension in diabetes; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 13 Nov 2007 Status changed from recruiting to discontinued. An improvement in pharmaceutical formulation is needed for this combination.
    • 04 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top